Latest News

Biomarkers after stopping treatment may identify at-risk MS patients


Increasing levels of neurofilament-light chain (NfL) and glial fibrillary acidic protein (GFAP) after drug discontinuation may identify previously stable MS patients at risk of new disease activity, according to Comprehensive Longitudinal Investigation of MS at the Brigham and Women’s Hospital (CLIMB) investigators (Bose et al. Neurol Neuroimmunol Neuroinflamm 2023;10:e200167; free full text at ). Read More

Exploring the lung-brain axis in MS


An emerging concept in MS research is the role of the lung microbiome in promoting disease severity, with preliminary evidence showing that pulmonary micro-organisms can regulate autoimmunity in the central nervous system (reviewed in Chen et al. Int J Mol Sci 2023;24:2170). Read More